[I-123/I-125]-RO-43-0463, A SITE-SPECIFIC TRACER FOR MAO-B MAPPING WITH AUTORADIOGRAPHY AS WELL AS WITH SPET

被引:3
作者
BEER, HF
FREY, LD
ROSSETTI, I
REMY, N
MAIER, A
SCHUBIGER, PA
机构
[1] PAUL SCHERRER INST, DIV RADIOPHARM, CH-5232 VILLIGEN, SWITZERLAND
[2] KANTONSSPITAL, DEPT NUCL MED, CH-5000 AARAU, SWITZERLAND
[3] UNIV ZURICH, INST PHARMACOL, CH-8006 ZURICH, SWITZERLAND
来源
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH | 1995年 / 15卷 / 1-4期
关键词
D O I
10.3109/10799899509045241
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The compound Ro 43-0463 [N-(2-aminoethyl)-5-iodo-2-pyridinecarboxamide)] is the iodo-analogue of Lazabemid (Ro 19-6327). The latter is well known to bind site specifically with K-D=15.7 nmol/l to the enzyme monoamine oxidase type B (MAO-B) which it inhibits (IC50=2*10(-8) mol/l) time dependently and reversibly. Ro 43-0463 having an IC50 of 3*10(-8) mol/l was labelled with I-123 as well as with I-125 to get a tool for measuring the MAO-B distribution autoradiographically and in the human brain with SPET (Single Photon Emission Tomography). The halogen exchange reaction of the bromo-precursor (Ro 18-4950) in the presence of CuSO4 and ascorbic acid was applied. The reaction conditions were optimized, varying the parameters time (30 to 105 min), precursor concentration (1 to 3.5 mg) and temperature (130 to 200 degrees C). The purification of [I-123/I-125]-Ro 43-0463 was performed on HPLC (Lichrosorb RP-18, 5 mu m, 250x8 mm) with 0.36 M H3PO4/EtOH 97/3 and 0.01 M (NH4)(2)HPO4 (1.5 ml/min) as eluent. The labelling yield was found to range between 60 and 70%. The activity concentration ranged between 18.5 and 37 MBq/ml. Autoradiography with rat brain slices was performed using 5 nM [I-125]-Ro 43-0463 in TRIS-buffer (pH 7.4) for 90 min at 20 degrees C. It showed a radioactivity pattern corresponding to the known distribution of MAO-B in the rat brain and proved, after displacement with L-Deprenyl (1 mu M), the high specificity of binding Ro 43-0463.
引用
收藏
页码:581 / 593
页数:13
相关论文
共 20 条
[1]  
BEER HF, 1992, APPL RADIAT ISOTOPES, V43, P781
[2]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[3]   MONOAMINE-OXIDASE, BRAIN AGING AND DEGENERATIVE DISEASES [J].
BENEDETTI, MS ;
DOSTERT, P .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (04) :555-561
[4]  
BERMAN DS, 1975, J NUCL MED, V16, P865
[5]   [H-3] RO-19-6327 - A REVERSIBLE LIGAND AND AFFINITY LABELING PROBE FOR MONOAMINE OXIDASE-B [J].
CESURA, AM ;
GALVA, MD ;
IMHOF, R ;
KYBURZ, E ;
PICOTTI, GB ;
DAPRADA, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (03) :457-465
[6]  
DAPRADA M, 1988, PROGR CATECHOLAMIN B, P359
[7]  
HAEFELY WE, 1990, ADV NEUROL, V53, P505
[8]  
HASLER PH, IN PRESS J NUCL BIOL
[9]  
JOSSAN SS, 1990, J NEUR TR S, P61
[10]  
KETTLER R, COMMUNICATION